- Vical (VICL -20%) approves the proposal to merge with Brickell Biotech and the transaction is expected to close on August 31, 2019.
- More news on: Vical Incorporated, Merger & acquisition news, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Vical Incorporated Company Name:
VICL Stock Symbol:
Market:
Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...
Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...
• Merger Transaction Expected to Close August 31, 2019 SAN DIEGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (“Vical”) (Nasdaq:VICL) announced that its stockholders voted to approve the proposals required to complete the merger transaction with Bric...